Company identified Nanobodies related to musculoskeletal disorders.

Ablynx reached a first milestone in its discovery and development collaboration with Procter & Gamble Pharmaceuticals (P&GP) establishing the potential of Ablynx’ Nanobody® technology for possible new treatments in the musculoskeletal category.


The Nanobody® technology has been used to rapidly identify a highly diverse and potent panel of Nanobodies® against one of the targets exclusive to the collaboration, triggering a milestone payment. 


As part of this on-going collaboration Ablynx is responsible for discovering Nanobodies® that meet an agreed product profile. P&GP is responsible for the pre-clinical and clinical development of Nanobodies® as well as the commercialization of any resulting drug products.

Previous articleVion Inks Manufacturing Deal for Anticancer Agent
Next articleSysmex and Afymetrix Sign Two Deals Related to Latter’s Microarray Products